Retinal Biologics Market Report 2026

The retinal biologics market size has grown rapidly in recent years. It will grow from $28.12 billion in 2025 to $31.28 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to rising prevalence of age-related macular degeneration, increasing diabetic population, clinical success of monoclonal antibody therapies, growing ophthalmology healthcare expenditure, improved diagnostic imaging technologies.

The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $49.03 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancements in retinal biologic drug delivery systems, expansion of pipeline biologics for retinal diseases, increasing adoption of personalized ophthalmic therapies, growth in emerging market ophthalmology infrastructure, rising demand for long-duration treatments. Major trends in the forecast period include long-acting retinal biologic formulations, increasing adoption of anti-vegf biologics, shift toward minimally invasive intraocular therapies, expansion of biologics for diabetic eye disorders, growth in specialty retina clinics.

The growing demand for personalized medicine is expected to drive growth in the retinal biologics market in the coming years. Personalized medicine customizes medical treatment based on an individual’s unique genetic profile, enabling more precise and effective healthcare interventions. In retinal biologics, personalized medicine is applied to tailor therapies according to a patient’s genetic and molecular characteristics, optimizing treatment outcomes while minimizing adverse effects. For example, in February 2024, the Personalised Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. This rising demand for personalized medicine is therefore fueling the retinal biologics market.

Key players in the retinal biologics market are focusing on advanced solutions such as bispecific antibodies to enhance treatment efficacy, reduce retinal damage, and improve visual outcomes. Bispecific antibodies are biologic therapies engineered to simultaneously target two disease pathways, offering superior therapeutic benefits. For instance, in May 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced that the U.S. FDA accepted its supplemental biologics license application (sBLA) for Vabysmo (faricimab) to treat macular edema following retinal vein occlusion (RVO). This approval was supported by two Phase III trials demonstrating early and sustained visual improvement, meeting the primary endpoint of non-inferiority to aflibercept. Vabysmo is the first bispecific antibody approved for ocular use to treat neovascular (‘wet’) age-related macular degeneration and diabetic macular edema. Further studies showed reduced retinal blood vessel leakage in Vabysmo-treated patients compared to those receiving aflibercept.

In January 2023, Coherus BioSciences Inc., a US-based biosimilar therapeutics company, acquired exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States for an undisclosed amount. This acquisition allows Coherus to expand its portfolio of anti-VEGF medications, significantly increasing its market opportunity and supporting mid- to long-term growth and revenue potential. Klinge Biopharma GmbH, a Germany-based company, specializes in anti-VEGF therapeutics.

Major companies operating in the retinal biologics market are Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Spark Therapeutics Inc., Bayer AG, Santen Pharmaceutical Co. Ltd., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Alimera Sciences Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Aerie Pharmaceuticals Inc., Ocular Therapeutix Inc., Fidia Farmaceutici S.p.A, Roche Holding AG, Amgen Inc., Biogen Inc., Genentech Inc., Allergan PLC.

North America was the largest region in the retinal biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created notable challenges for the retinal biologics market by increasing costs associated with imported biologic raw materials, sterile manufacturing equipment, and cold-chain logistics required for intraocular therapies. These impacts are most pronounced in drug classes such as VEGF-A antagonists and TNF-α inhibitors, as well as in regions dependent on cross-border pharmaceutical trade, including Asia-Pacific and parts of Europe. Higher tariffs have pressured pricing and slowed hospital and specialty clinic adoption in cost-sensitive markets. However, tariffs have also encouraged local biologics manufacturing, regional supply chain diversification, and investments in domestic biopharmaceutical capabilities, creating long-term resilience opportunities for the market.

The retinal biologics market research report is one of a series of new reports that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinal biologics are bioengineered macromolecules implanted in the eyes to treat chronic retinal diseases. They are highly targeted compounds that modulate inflammatory mediators to manage inflammatory, corneal, and retinal conditions.

The main types of retinal biologics include vascular endothelial growth factor (VEGF)-A antagonists and tumor necrosis factor (TNF)-A inhibitors. A VEGF-A antagonist blocks the activity of vascular endothelial growth factor, a key angiogenic factor essential for vascular endothelial cell growth. These biologics are used for conditions such as macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are available through hospitals, pharmacies, specialty clinics, online pharmacies, and other healthcare channels.

The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.